Best Ophthalmology Companies in Massachusetts, United States
The 51 best Ophthalmology companies in Massachusetts, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Avedro.
Ranked: Best Ophthalmology companies in Massachusetts
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Avedro Developer of corneal collagen cross-linking technology | $211M | 99 mo ago | 113 | — | — | 374 patents Corneal cross‑linking devices and diagnostics for ophthalmic treatment and eye‑tracking. | — |
| 2 | Alkeus Pharmaceuticals Developing Treatments for Dry-AMD & Stargardt disease | $150M | 38 mo ago | 6 | Leonide Saad Founder | WordPressMySQLPHP+16 | — | — |
| 3 | EyePoint Pharmaceuticals Developer of small molecule-based therapeutics for treating ophthalmic disorders | $135M | 67 mo ago | 49 | — | WordPress Block EditorWordPressApple iCloud Mail+18 | 148 patents Biodegradable ocular drug delivery inserts and Tie-2 activating biologic therapeutics. | 1 award |
| 4 | pSivida Drug delivery systems | $128M | 100 mo ago | 49 | — | — | 224 patents Patents concentrated in health & consumer products | — |
| 5 | NinePoint Medical Advanced medical imaging for real-time tissue microstructure visualization and analysis | $98M | 128 mo ago | 25 | — | — | — | — |
| 6 | Vedere Developer of gene therapy for vision restoration | $98M | 62 mo ago | 5 | — | — | — | — |
| 7 | INTERGALACTIC THERAPEUTICS Developer of gene therapies for the treatment of multiple diseases | $75M | 57 mo ago | 34 | — | — | — | — |
| 8 | Ocular Therapeutix Developer of ophthalmic therapeutics using hydrogel technology | $67M | 157 mo ago | 267 267 → 352 (+32%) | — | WordPressApple iCloud MailMySQL+30 | 237 patents Sustained-release ocular implants delivering kinase inhibitors and immunosuppressants. | 1 internship |
| 9 | Stargazer Pharmaceuticals Provider of therapeutics for Stargardt disease | $57M | 68 mo ago | — | Gary Sternberg CEO | — | — | — |
| 10 | Aviceda Therapeutics Developer of biotherapeutics for glycol-immune diseases | $47M | 19 mo ago | 16 | Christopher Scott Co-Founder | — | — | — |
| 11 | Stellular Bio Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells 37Funding top 28%Talent top 28%Moat bottom 38%Global bottom 37% All 5 signals ▾Fundingtop 28% Talenttop 28% Moatbottom 38% Globalbottom 37% Marketbottom 32% Funding: Raised $44.5M across 9 rounds · 9 rounds over 10 yrs (0.9/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 37/100 | $44M | 6 mo ago | 12 | Joseph Italiano Co-Founder | — | — | — |
| 12 | EyeGate Affordable medications and healthcare products provider with a focus on customer well-being | $44M | 59 mo ago | 12 | — | Cart FunctionalityWordPressMySQL+10 | — | — |
| 13 | OcuTerra Therapeutics Developer of eye drop to treat diabetic eye disease | $40M | 31 mo ago | 4 | — | — | — | — |
| 14 | Epion Therapeutics Developer of minimally-invasive treatments for corneal ectatic diseases | $32M | 46 mo ago | — | Mike Webb Chief Executive Officer & Board Member | Cart FunctionalitySquarespace CommerceSquarespace+27 | — | — |
| 15 | Advanced Cell Technology Developer of stem-cell-based treatments in the field of regenerative medicine | $25M | 187 mo ago | — | Ray Parvin CEO | — | 400 patents Molecular diagnostics and protein interaction assays using in situ hybridization and imaging | — |
| 16 | Adaptilens Developer of intraocular lens | $19M | 27 mo ago | 5 | Liane Clamen Founder & CEO | — | 14 patents Biostable polymer brush materials and delivery mechanisms for advanced intraocular lenses | — |
| 17 | Solx Non-custodial Solana wallet and crypto payments inside Telegram | $11M | 116 mo ago | 2 | — | — | 16 patents Ocular drainage shunt devices and methods for glaucoma treatment | — |
| 18 | Cirrus Therapeutics Developer of therapies designed to extend ocular healthspan and restore vision | $11M | 12 mo ago | — | Andrew Dick Co-Founder | — | — | 1 award |
| 19 | Bikam Pharmaceuticals Small molecule therapeutics for degenerative eye diseases | $11M | 225 mo ago | — | Bill Brubaker CEO | — | — | — |
| 20 | Aramis Biosciences Developer of therapies to treat ocular surface disease | $10M | 55 mo ago | 5 | David Tierney CEO | — | — | — |
| 21 | GelMEDIX Developer of a hydrogel drug delivery technology for ophthalmic treatment | $6M | 5 mo ago | 9 | Nasim Annabi Co-Founder | — | 26 patents Hydrogel biomaterials for cell encapsulation and tissue engineering applications. | — |
| 22 | Aldeyra Developer of drugs for the treatment of immune-mediated diseases | $5M | 72 mo ago | 30 | — | DrupalPHPZURB Foundation+23 | — | — |
| 23 | Hemera Biosciences Pre clinical gene therapy company developing anti-complement gene therapy to treat AMD | $4M | 160 mo ago | 1 | — | — | — | — |
| 24 | Neuroptika Discovering and developing regenerative treatments for ophthalmic diseases | $3M | 90 mo ago | 2 | Chiho Fukiage Co-Founder | — | — | — |
| 25 | Ocata Therapeutics Stem cell-based therapies to treat dry age-related macular Degeneration (Dry AMD) and stargardt’s macular… | $3M | 131 mo ago | 37 | — | — | — | — |
| 26 | Anew Optics Developer of intraocular lens ophthalmic disorders | $3M | 163 mo ago | — | — | — | 39 patents Intraocular lens haptic structures and capsular opacification‑blocking designs | — |
| 27 | Pykus Therapeutics Develops a dissolvable intraocular device for use during retinal surgery | $2M | 66 mo ago | 8 | — | — | — | — |
| 28 | AbFero Pharmaceuticals Developer of oral iron chelators for the treatment of iron overload diseases | $2M | 64 mo ago | 3 | Raymond Bergeron Co-Founder & CSO | — | — | — |
| 29 | Helio Vision Developer of small molecule based therapeutics for the treatment of eye diseases | $2M | 97 mo ago | — | Josef von Rickenbach Co-Founder & CEO | — | — | — |
| 30 | InGel Regenerative cell-therapy platform for researchers | $350K | 47 mo ago | 6 | Deepti Singh Co-Founder | — | — | — |
| 31 | Akeyna Developer of medical device for ophthalmic diseases | $300K | 13 mo ago | — | Karen Cronholm Co-Founder & CEO | — | — | — |
| 32 | Amorphex Developer of drug delivery device for ophthalmic diseases | $265K | 42 mo ago | — | Charles Leahy Founder | — | — | — |
| 33 | LayerBio Developing innovative ophthalmic therapies, including sustained-release drug delivery for cataract surgery | $205K | 73 mo ago | 3 | — | — | 19 patents Ocular drug‑delivery devices and methods for targeted eye medication administration | — |
| 34 | Intelon Optics Provider of smart technology for the treatment of cornea & other ocular structures related to eye health | $100K | 10 mo ago | 15 | Dimitri Chernyak CEO | — | 22 patents Patents concentrated in computing, sensing & instrumentation | — |
Top 12 Ophthalmology companies in Massachusetts
#1
Series A · Watertown, Massachusetts · founded 2014 · 12 employees$44.5Mraised▾
Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells. It offers programmable logic controller platform focused on modifying the regenerative power of platelets, enabling researchers to create reengineering cell therapies.
- Jan 2026Series A—
- Mar 2025Grant (prize money)$356.5K
- Aug 2019Series A$26.4M
- May 2017Series A$10M
#2
Seed · Newton, Massachusetts · founded 2019 · 9 employees$6.4Mraised▾
Developer of a hydrogel drug delivery technology for ophthalmic treatment. It offers a lead product GMX-101 a retinal pigment epithelial (RPE) cell therapy that targets Geographic Atrophy.
- Feb 2026Seed$13M
- Oct 2025Seed$542K
- Jan 2025Seed$1M
- Mar 2024Conventional Debt$1.9M
#3
Series C · Cambridge, Massachusetts · founded 2018 · 16 employees$47.2Mraised▾
Developer of biotherapeutics for glycol-immune diseases. The pipeline products are for eye diseases, fibrosis, neurology, and oncology. For eye diseases AVD-104, AVD-302, AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma respectively. AVD-601, AVD-701, and AVD-801 for oncology, neurology, and fibrosis respectively.
- Dec 2024Series C$207.5M
- May 2024Series C$18.9M
- May 2023Series B$15.6M
- Mar 2022Series B$8.4M
#4
Seed · Cambridge, Massachusetts · founded 2021$11Mraised▾
Developer of therapies designed to extend ocular healthspan and restore vision. The company focuses on age-related macular degeneration treatments by rejuvenating the eye’s defenses across multiple pathways. Their pioneering research offers a preventative and restorative therapy with the potential to slow or halt disease progression and reverse early signs of vision loss. The company’s therapeutic approach delivers genetic instructions directly into the eye, restoring balance, reducing inflammation, and protecting cells essential for clear vision.
- Aug 2025Seed$11M
#5
Series B · Boston, Massachusetts · founded 2010 · 6 employees$150Mraised▾
Alkeus Pharmaceuticals is developing a new treatment for dry age-related macular degeneration and Stargardt disease. Its lead product ALK-001, an orally delivered compound has been found to prevent the formation and accumulation of toxic ocular pigments called "vitamin A dimers" and preserving visual function in preclinical studies. ALK-001 is currently being tested in a Phase 2 trial for the treatment of Stargardt disease.
- Jun 2023Series B$150M
- Jul 2018Grant (prize money)$1.8M
- Aug 2014Grant (prize money)$165.2K
- Sep 2013Grant (prize money)$416K
#6
Deadpooled · Boston, Massachusetts · founded 2020 · 4 employees$40.2Mraised▾
Developer of eye drop to treat diabetic eye disease. The lead drug OTT166 is a topical integrin inhibitor used for the treatment of diabetic macular edema and neovascular age-related macular degeneration.
- Dec 2023Series B$25.6M
- Apr 2021Series B$14.6M
#7
Series A · Newton, Massachusetts · founded 2018 · 5 employees$19.1Mraised▾
Adaptilens has developed intraocular lens that is injected into the eyes. The company has developed Adaptilens that's designed to be injected into the eye to retain its elliptical shape by allowing the ciliary muscles of the eyes to modify the lens shape and focus on the objects to view them clearly.
- Apr 2024Series A$17.5M
- Jun 2021Grant (prize money)$87.5K
- Nov 2020Seed$1.6M
#8
Seed · Boston, Massachusetts · founded 2022$300Kraised▾
Developer of medical device for ophthalmic diseases. It offers smart needle detects blood vessels to prevent severe complications such as blindness which can occur when blood vessels are occluded with dermal fillers.
- Jul 2025Seed$300K
#9
Early Stage · Woburn, Massachusetts · founded 2011 · 15 employees$100Kraised▾
Intelon is a provider of smart technology for the treatment of cornea & other ocular structures related to eye health. It has developed BOSS a unique technology to assess biomechanical properties of the cornea and other critical eye diseases. It uses tomographic imaging that is used to determine thickness, curvature and other morphological parameters to assess structural dimensions form and shape of the cornea.
- Sep 2025Grant (prize money)$566.3K
- Jan 2025Grant (prize money)$1.2M
- Jun 2018Grant (prize money)$1.4M
#10
Public · Watertown, Massachusetts · founded 1987 · 49 employees$134.5Mraised▾
Developer of small molecule-based therapeutics for treating ophthalmic disorders. The company has developed its proprietary technology Durasert which is a miniaturized, injectable, sustained-release drug delivery system for small molecules. The company's lead product candidates are Yutiq for chronic non-infectious uveitis, and EYEP-1901 for wet AMD, diabetic retinopathy, and retinal vein occlusion.
- Jan 2021Post IPO$15.7M
- Feb 2019Conventional Debt$60M
- Oct 2018Post IPO$28.9M
- Mar 2018Post IPO$9.9M
#11
Acquired · Waltham, Massachusetts · founded 2007 · 113 employees$210.8Mraised▾
Developer of corneal collagen cross-linking technology. Its products, the VibeX and KXL System for performing Lasik Xtra and accelerated cross-linking have been commercialized outside the US. It also received approval from the China FDA for its KXL system in Nov 2015.
- May 2018Series E$25M
- Apr 2017Series E$42M
- Apr 2017Conventional Debt—
- Nov 2015Series E$32M
#12
Acquired · Cambridge, Massachusetts · founded 2019 · 5 employees$98Mraised▾
Vedere is the developer of gene therapy for vision restoration. The platform is developing gene therapy for inherited retinal degenerations (IRDs) vision loss and also for both genetic and nongenetic vision loss.
- May 2021Series A$77M
- Jun 2019Series A$21M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Ophthalmology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Medical Devices in Massachusetts is moving
A read on the academic research around Medical Devices in Massachusetts — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 49 papers.
- Massachusetts General Hospital24
- Massachusetts Institute of Technology13
- University of Massachusetts Amherst5
- Massachusetts Eye and Ear Infirmary5
- Massachusetts School of Law2
- Robot3
- In vivo2
- Nanotechnology2
- Compromise2
- Medical record2
- Biomedical engineering2
- Robot2
- Robustness (evolution)1
- Flexibility (engineering)1
- Surgical robot1
- Food and drug administration1→3
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.